Digest Network Come funziona
Network
/
Società
Id
Non verificato

Idorsia Pharmaceuticals Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceutica

71 comunicati stampa

Guarda tutti i comunicati
27/04/2026
Farmaceutica
Annunci Economici
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmaceutica
Annunci Economici
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/04/2026
Farmaceutica
Annunci Economici
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
29/03/2026
Farmaceutica
Annunci Economici
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
23/03/2026
Farmaceutica
Annunci Economici
Idorsia announces the nomination of three candidates for election to the Board of Directors
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
15/03/2026
Farmaceutica
Annunci Economici
Idorsia announces management change
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/03/2026
Farmaceutica
Annunci Economici
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
25/02/2026
Farmaceutica
Annunci Economici
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
12/02/2026
Farmaceutica
Annunci Economici
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/02/2026
Farmaceutica
Annunci Economici
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0